263 related articles for article (PubMed ID: 37502435)
41. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy.
Han X; Luo Z; Wang W; Zheng P; Li T; Mei Z; Wang J
Front Pharmacol; 2021; 12():696065. PubMed ID: 34690751
[No Abstract] [Full Text] [Related]
42. Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy.
Singh J; Sharma BC; Puri V; Sachdeva S; Srivastava S
Metab Brain Dis; 2017 Apr; 32(2):595-605. PubMed ID: 28070704
[TBL] [Abstract][Full Text] [Related]
43. Clinical study of probiotics combined with lactulose for minimal hepatic encephalopathy treatment.
Shi J; Li F
Eur J Gastroenterol Hepatol; 2023 Jul; 35(7):777-781. PubMed ID: 37161982
[TBL] [Abstract][Full Text] [Related]
44. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
Jain L; Sharma BC; Srivastava S; Puri SK; Sharma P; Sarin S
J Gastroenterol Hepatol; 2013 Jul; 28(7):1187-93. PubMed ID: 23425082
[TBL] [Abstract][Full Text] [Related]
45. A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study.
Fagan A; Gavis EA; Gallagher ML; Mousel T; Davis B; Puri P; Sterling RK; Luketic VA; Lee H; Matherly SC; Sanyal AJ; Stravitz RT; Patel V; Siddiqui MS; Asgharpour A; Fuchs M; Thacker L; Bajaj JS
J Hepatol; 2023 Feb; 78(2):312-321. PubMed ID: 36152764
[TBL] [Abstract][Full Text] [Related]
46. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy.
Shukla S; Shukla A; Mehboob S; Guha S
Aliment Pharmacol Ther; 2011 Mar; 33(6):662-71. PubMed ID: 21251030
[TBL] [Abstract][Full Text] [Related]
47. Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial.
Alvares-da-Silva MR; de Araujo A; Vicenzi JR; da Silva GV; Oliveira FB; Schacher F; Oliboni L; Magnus A; Kruel LP; Prieb R; Fernandes LN
Hepatol Res; 2014 Sep; 44(9):956-63. PubMed ID: 24033861
[TBL] [Abstract][Full Text] [Related]
48. Prevalence of Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Cross-Sectional, Clinicoepidemiological, Multicenter, Nationwide Study in India: The PREDICT Study.
Rathi S; Chopra M; Chouduri G; Sharma P; Madan K; Chhabra M; Rai RR; Govil A; Konar A; Goenka M; Agarwal M; Mukherjee J; Thorat V; Salunkhe S; Abraham P; Nagral A; Jhaveri A; Bhat N; Varghese J; R S A; Ravishankar ; Reddy DC; Dhiman RK
J Clin Exp Hepatol; 2019; 9(4):476-483. PubMed ID: 31516264
[TBL] [Abstract][Full Text] [Related]
49. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.
Lunia MK; Sharma BC; Sharma P; Sachdeva S; Srivastava S
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1003-8.e1. PubMed ID: 24246768
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of Zinc Supplement in Minimal hepatic Encephalopathy: A prospective, Randomized Controlled Study (Zinc-MHE Trial).
Janyajirawong R; Vilaichone RK; Sethasine S
Asian Pac J Cancer Prev; 2021 Sep; 22(9):2879-2887. PubMed ID: 34582657
[TBL] [Abstract][Full Text] [Related]
51. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
52. Probiotics are beneficial for liver cirrhosis: a systematic review and meta-analysis of randomized control trials.
Yang X; Lei L; Shi W; Li X; Huang X; Lan L; Lin J; Liang Q; Li W; Yang J
Front Med (Lausanne); 2024; 11():1379333. PubMed ID: 38618195
[TBL] [Abstract][Full Text] [Related]
53. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK
Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444
[TBL] [Abstract][Full Text] [Related]
54. Management of overt hepatic encephalopathy.
Sharma P; Sharma BC
J Clin Exp Hepatol; 2015 Mar; 5(Suppl 1):S82-7. PubMed ID: 26041964
[TBL] [Abstract][Full Text] [Related]
55. The diagnosis and treatment of minimal hepatic encephalopathy.
Zhan T; Stremmel W
Dtsch Arztebl Int; 2012 Mar; 109(10):180-7. PubMed ID: 22470407
[TBL] [Abstract][Full Text] [Related]
56. Management of hepatic encephalopathy in the hospital.
Leise MD; Poterucha JJ; Kamath PS; Kim WR
Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
[TBL] [Abstract][Full Text] [Related]
57. A meta-analysis of microbiome therapies for hepatic encephalopathy.
Gao J; Nie R; Chang H; Yang W; Ren Q
Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):927-937. PubMed ID: 37505972
[TBL] [Abstract][Full Text] [Related]
58. Treatment of minimal hepatic encephalopathy.
Kumashiro R
Hepatol Res; 2008 Nov; 38 Suppl 1():S128-31. PubMed ID: 19125944
[TBL] [Abstract][Full Text] [Related]
59. Effect of different treatments and alcohol addiction on gut microbiota in minimal hepatic encephalopathy patients.
Zuo Z; Fan H; Tang XD; Chen YM; Xun LT; Li Y; Song ZJ; Zhai HQ
Exp Ther Med; 2017 Nov; 14(5):4887-4895. PubMed ID: 29201193
[TBL] [Abstract][Full Text] [Related]
60. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
